Implantable
cardiac pacemaker is a small device implanted in the chest or
abdomen for the treatment of abnormal heart rhythms, arrhythmia,
heart block, and atrial fibrillation. Implantable cardiac pacemaker
is evolved from battery-powered transistorized wearable pacemakers to
current leadless pacemaker, an entire pacemaker which is placed
within cardiac chambers. Cardiac pacemakers are used to treat
abnormal electrical signaling in the heart, which causes arrhythmias.
Implantable cardiac pacemaker use low-energy electrical signals to
speed up the slow heartbeat, help to control an abnormal and fast
heart rhythm, and prevents long QT syndrome, a disorder of the
heart’s electrical activity, which causes sudden, uncontrollable,
and dangerous arrhythmias.
Ask
For In-Depth Sample Copy @
https://www.coherentmarketinsights.com/insight/request-sample/1663
Market
Dynamics:
Market
players are engaged in developing novel pacemakers with ability to
control the abnormal heart rhythm, monitor and record patient’s
heart's electrical activity, blood temperature, and breathing rate.
Technological advances in the field of implantable cardiac pacemakers
along with increasing prevalence of cardiovascular disease is
projected to drive the growth of implantable cardiac pacemaker market
over the forecast period.
The
global implantable cardiac pacemaker market was valued at US$ 4.7
billion in 2017 and is expected to witness a CAGR of 7.1% over the
forecast period (2018 – 2026).
Top
Key Players:
Some
of the key players operating in implantable cardiac pacemaker market
include Medtronic plc, BIOTRONIK, Inc., Boston Scientific
Corporation, St. Jude Medical, Vitatron Holding B.V., Shree
Pacetronix Ltd., MEDICO S.p.A., Lepu Medical Technology Co Ltd.,
LivaNova PLC, and Qinming Medical.
Introduction
of Advanced Pacemaker Technologies is Expected to Drive Growth of the
Implantable Cardiac Pacemaker Market
Adoption
of advanced technologies in cardiac pacemakers such as MRI
safe-pacemakers, pacemakers with improved battery life, delay the
progression of persistent Atrial Fibrillation (AF) in patients
suffering from bradycardia and wireless automated technologies. This
advancements are gaining significant traction of various market
players of implantable cardiac pacemakers with affordable costs,
which in turn are expected to drive growth of implantable cardiac
pacemakers market. For instance, in February 2017, Abbott received
the Food and Drug Administration (FDA) approval for its
MR-conditional labeling for both of its products i.e. Assurity MRI
pacemaker and the Tendril MRI pacing lead. Furthermore, introduction
of advance technology such as wireless and automated pacemaker
monitoring pacemakers are gaining significant traction among
healthcare providers.
Detailed
Segmentation:
•
Global Implantable Cardiac Pacemaker Market, By Product Type:
-
Single Chamber Pacemaker
-
Dual Chamber Pacemaker
-
Biventricular Pacemaker
•
Global Implantable Cardiac Pacemaker Market, By Application:
-
Heart Block
-
Arrhythmia
-
Atrial fibrillation
-
Long QT Syndrome
-
Bradycardia
-
Tachycardia
-
Others
Request
For Customization of This Exclusive Report @
https://www.coherentmarketinsights.com/insight/request-customization/1663
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment